Neither of the parties endorse or suggest any commercial products, services, or equipment.. 2-year advanced melanoma survival benefit with dabrafenib, trametinib combination By Shreeya Nanda, Senior medwireNews Reporter Updated outcomes from the COMBI-v trial show significantly improved overall and progression-free of charge survival with first-line dabrafenib in addition trametinib weighed against vemurafenib in individuals with advanced melanoma. The results of the stage III trial comprising individuals with BRAF V600E/K mutation-positive unresectable or metastatic melanoma were presented at the European Cancer Congress in Vienna, Austria, by Caroline Robert, from the Institut Gustave Roussy in Paris, France. A previous interim evaluation with a median follow-up of 11 a few months showed a significant improvement in OS with dabrafenib and trametinib, explained Robert in her presentation, so much so that the trial was terminated early and sufferers in the vemurafenib group were permitted to crossover.Related StoriesRebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infectionData displays romosozumab much better than teriparatide in increasing bone strength in postmenopausal womenAmgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma TO MEET UP Nanjing Zhongshan Life Science Park at L17 in Hall A. Bio Alps Taking advantage of the brand new FTA between Switzerland and China, Bio Alps, the life research cluster of Western Switzerland, will lead a delegation of 8 Swiss companies to 2014 Biotech China. Bio Alps promotes synergies between academia, entrepreneurs, investors, authorities and fresh businesses to translate tips into new products and bring new technology to market. To contact Bio Alps, please visit the booth F17 in Hall A.
3D-printed models of children’s brain anatomy help reduce operative risk of complex procedures Boston Kids's Hospital doctors report the first situations of children benefiting from 3D printing of their anatomy before undergoing high-risk brain techniques.